# Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias

> **NCT00472849** · PHASE1,PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 92 (actual)

## Conditions studied

- Richter's Transformation
- Leukemia

## Interventions

- **DRUG:** Oxaliplatin
- **DRUG:** Fludarabine
- **DRUG:** Cytarabine
- **DRUG:** Rituximab
- **DRUG:** Pegfilgrastim

## Key facts

- **NCT ID:** NCT00472849
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2013-11-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472849

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472849, "Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation and Leukemias". Retrieved via AI Analytics 2026-07-17 from https://api.ai-analytics.org/clinical/NCT00472849. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*